Ofatumumab (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ofatumumab" in French language version.

refsWebsite

Global rank French rank

2^nd place

3^rd place

low place

4,913^th place

low place

7,741^st place

1sciencedirect.com

149^th place

80^th place

1ashpublications.org

low place

low place

674^th place

38^th place

4^th place

12^th place

2,374^th place

298^th place

20minutes.fr

« Novartis rachète sur les droits d'un médicament contre la sclérose en plaques » (consulté le 25 août 2015)

ascopubs.org

jco.ascopubs.org

(en) Wierda WG, Kipps TJ, Mayer J et al. « Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia » J Clin Oncol. 2010;28:1749-55.

ashpublications.org

(en) Maiti A, Kantarjian HM, Ravandi F et al., « Hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia: updated results of a phase II trial », Blood, vol. 130, n^o Supplement 1,‎ 2017, p. 3876. (DOI 10.1182/blood.V130.Suppl_1.3876.3876, lire en ligne [html])

doi.org

dx.doi.org

(en) Maiti A, Kantarjian HM, Ravandi F et al., « Hyper-CVAD plus ofatumumab as frontline therapy in CD20+ acute lymphoblastic leukemia: updated results of a phase II trial », Blood, vol. 130, n^o Supplement 1,‎ 2017, p. 3876. (DOI 10.1182/blood.V130.Suppl_1.3876.3876, lire en ligne [html])
(en) Hauser SL, Bar-Or A, Cohen JA, Comi G, Kappos L, Asclepios I et Asclepios II trial et al., « Ofatumumab versus Teriflunomide in Multiple Sclerosis », N Engl J Med, vol. 383, n^o 6,‎ 2020, p. 546-57. (PMID 32757523, DOI 10.1056/NEJMoa1917246, lire en ligne [html])

jimmunol.org

(en) Beum PV, Lindorfer MA, Beurskens F et al. « Complement activation on B Lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis » J Immunol. 2008;181:822-32.

nejm.org

(en) Hauser SL, Bar-Or A, Cohen JA, Comi G, Kappos L, Asclepios I et Asclepios II trial et al., « Ofatumumab versus Teriflunomide in Multiple Sclerosis », N Engl J Med, vol. 383, n^o 6,‎ 2020, p. 546-57. (PMID 32757523, DOI 10.1056/NEJMoa1917246, lire en ligne [html])

nih.gov

ncbi.nlm.nih.gov

(en) Hauser SL, Bar-Or A, Cohen JA, Comi G, Kappos L, Asclepios I et Asclepios II trial et al., « Ofatumumab versus Teriflunomide in Multiple Sclerosis », N Engl J Med, vol. 383, n^o 6,‎ 2020, p. 546-57. (PMID 32757523, DOI 10.1056/NEJMoa1917246, lire en ligne [html])

sciencedirect.com

(en) Hillmen P, Robak T, Janssens A et al. « Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial » Lancet 2015;385:1873-83.